tiprankstipranks
COMPASS Pathways (DE:5Y6)
FRANKFURT:5Y6
Germany Market
5Y6
COMPASS Pathways
RESEARCH TOOLSreports

COMPASS Pathways (5Y6) Stock News & Sentiment

4 Followers
Strong Efficacy, Favorable Safety, and Limited Competition Drive Buy Rating on COMPASS Pathways’ COMP360
Premium
Ratings
Strong Efficacy, Favorable Safety, and Limited Competition Drive Buy Rating on COMPASS Pathways’ COMP360
10d ago
CMPS
Compass Pathways: Strengthened Balance Sheet, Advancing COMP360 Through Pivotal Milestones Supports Buy Rating
Premium
Ratings
Compass Pathways: Strengthened Balance Sheet, Advancing COMP360 Through Pivotal Milestones Supports Buy Rating
13d ago
CMPS
COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating
Premium
Ratings
COMPASS Pathways: Durable Psychedelic Therapy Profile and Clear Path to 2027 Approval Support Buy Rating
25d ago
CMPS
3 Best Stocks to Buy in Today’s Volatile Market, 3/4/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy in Today’s Volatile Market, 3/4/2026, According to Top Analysts
1M ago
BOBS
CMPS
Cathie Wood Scoops Up $24M in Figma, Sells DraftKings
Premium
Market News
Cathie Wood Scoops Up $24M in Figma, Sells DraftKings
2M ago
FIG
ARKG
COMPASS Pathways Announces $150 Million Public Offering
Premium
Company Announcements
COMPASS Pathways Announces $150 Million Public Offering
2M ago
8K
CMPS
Robust Phase 3 Efficacy and Clean Safety Profile Drive Buy Rating on COMPASS Pathways’ CMPS
Premium
Ratings
Robust Phase 3 Efficacy and Clean Safety Profile Drive Buy Rating on COMPASS Pathways’ CMPS
2M ago
CMPS
More DE:5Y6 News >

5Y6 News on the Web

Strong Efficacy, Favorable Safety, and Limited Competition Drive Buy Rating on COMPASS Pathways’ COMP360
TipRanks News
Bullish
LifeSci Capital Keeps Their Buy Rating on COMPASS Pathways (CMPS)
TipRanks News
Neutral
Compass Pathways: Strengthened Balance Sheet, Advancing COMP360 Through Pivotal Milestones Supports Buy Rating
TipRanks News
Bullish
Psychedelic: Compass Pathways, NRx Pharma report earnings results
TipRanks News
Bullish
RBC Capital Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Ionis Pharmaceuticals (IONS)
TipRanks News
Bullish
Compass Pathways price target lowered to $18 from $20 at Canaccord
TipRanks News
Neutral
Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:5Y6’s Media Buzz Sentiment?
Currently, no data Available
What is DE:5Y6’s weekly average amount of articles?
Currently, no data Available
What is DE:5Y6’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
NBIXNeurocrine
STAAStaar Surgical
AORTArtivion
OWLTOwlet
HUMHumana
Showing the stocks with the most bullish news sentiment over the past week